Cetuximab in cancers of the lung and head & neck

ES Kim, EE Vokes, MS Kies - Seminars in oncology, 2004 - Elsevier
The treatment of aerodigestive tract tumors remains difficult despite improved techniques in
detection, surgery, radiation, and chemotherapy. Therefore, strategies to improve efficacy in …

Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum …

M Knoedler, TC Gauler, V Gruenwald, A Matzdorff… - Oncology, 2013 - karger.com
Background: Cetuximab and docetaxel have single-agent activity in squamous cell
carcinoma of the head and neck (SCCHN). The efficacy of their combination was evaluated …

Treatment of head and neck cancers: issues for clinical pharmacists

SL Scarpace, FA Brodzik, S Mehdi… - … : The Journal of Human …, 2009 - Wiley Online Library
Head and neck cancers are a heterogeneous group of diseases involving the oral cavity,
pharyngeal tube, and larynx. Given the drug therapy options available, clinical pharmacists …

[HTML][HTML] Progress in head-and-neck cancer: Promise versus reality

T Gupta, JP Agarwal - Journal of Head & Neck Physicians and …, 2021 - journals.lww.com
Journal of Head & Neck Physicians and Surgeons¦ Volume 9¦ Issue 1¦ January-June 2021 2
imaging for guiding selective dose-escalation might further improve outcomes during high …

Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial

F Rivera, A García-Castaño, N Vega… - Expert review of …, 2009 - Taylor & Francis
Expression of EGF receptor (EGFR) is frequently elevated in squamous cell carcinoma of the
head and neck (SCCHN). Cetuximab is an anti-EGFR monoclonal antibody that has been …

[引用][C] Adding Cetuximab to Chemoradiation Did Not Benefit Patients With Advanced Head and Neck Cancer: What Were the Reasons

A Eisbruch - ASCO Post, 2014

Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell …

JB Vermorken, R Mesia, ME Vega-Villegas… - Journal of Clinical …, 2006 - ascopubs.org
5537 Background: The epidermal growth factor receptor (EGFR) is expressed in nearly all
SCCHN and carries a strong prognostic significance, providing the rationale for using EGFR …

A phase 2, multicenter, open-label study to evaluate the efficacy and safety of CDX-3379 in combination with cetuximab in patients with advanced head and neck …

JE Bauman, NF Saba, D Adkins, Y Wang, Y He… - 2018 - ascopubs.org
TPS6091 Background: ErbB3 (HER3) and its ligand, neuregulin-1 (NRG1), are widely
expressed in HNSCC and associated with tumor progression. ErbB3 may provide a key …

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer

MA Tejani, RB Cohen, R Mehra - Biologics: Targets and Therapy, 2010 - Taylor & Francis
Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC)
continues to be a source of significant morbidity and mortality worldwide. Agents that target …

Cetuximab: a standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck

J Bernier - Oncology Reviews, 2009 - Springer
The burden of squamous cell carcinoma of the head and neck (SCCHN) on healthcare
systems is expected to rise in line with projected increases in population sizes in general …